The latest 10-Q including revenue and a significant number of patents is late because they're doing fully audited financials for CytoBioscience and SolubleBioScience both of which are being rolled into WASM. https://backend.otcmarkets.com/otcapi/company/sec-filings/12760401/content/html Which turns out to be a chance for others to get in before The Street.
After the merger is finalized: A/S 100,000,000 O/S 54,382,961 (Over 53 million are restricted) Float 761,750
CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition. Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money. Video:
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work. The company is engaged with both private and public partners globally, including the FDA."
CytoBioScience has 4 locations: San Antonio, TX New Orleans, LA Birmingham, AL Cologne, Germany
The officers and (B Of D) are all giants in their fields: James R. Garvin, PhD Chief Executive Officer, President, and Director Thomas Knott, PhD Chief Science Officer and Director Henry C. Bourg, CPA Chief Financial Officer Paul Castella, PhD Director Ian Clements Director Alan Dean Director Shing Leong Hui Director Sue Lynn Hui Director https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140673149
Contact info: Dr. James Garvin, PhD j.garvin@cytobioscience.com info@CytoBioScience.com (210)-767-2727
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.